Fibrocell Science Appoints New Interim Chief Financial Officer


Kimberly M. Smith is new interim chief financial officer, treasurer and corporate secretary at Fibrocell Science, Inc.

David Pernock
David Pernock

David Pernock, Fibrocell’s chairman and CEO, thanked former CFO Gregory Weaver for his contributions to the firm and said they plan to conduct an executive search for a permanent CFO.

Smith will also continue to be controller, a position she has held since January 2014. Prior to joining Fibrocell, Smith was a financial consultant with AC Lordi.  From 2010 to 2013 she worked exclusively for Lordi’s client ViroPharma.

A certified public accountant with chartered global management account designation, Smith began her career with Ernst & Young in 1998.

“Kimberly has a strong background in accounting and finance, and we are confident that she is well-suited for these additional responsibilities,” said Christine St.Clare, chairman of the firm’s audit committee.

The autologous cell therapy company is developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs.


Connect With Your Community

Subscribe to stay informed!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.